Terushisa Nakamura

Learn More
SUMMARY Odanacatib is a cathepsin K inhibitor investigated for the treatment of postmenopausal osteoporosis. Phase 2 data indicate that 50 mg once weekly inhibits bone resorption and increases bone mineral density, with only a transient decrease in bone formation. We describe the background, design and participant characteristics for the phase 3(More)
For publicly posted protocols, Merck redacts the background and rationale sections because these sections may contain proprietary information. Merck also redacts the names of any individuals due to privacy issues. The appendices generally are not provided because they may be lengthy and contain non-essential information. The publicly posted protocol(More)
Serum concentration of thiobarbituric acid (TBA) reactants in the hepatic vein were measured before and after transient dearterialization of the liver in five human subjects bearing unresectable hepatocellular carcinoma (HCC). During 1 hour of the occlusion of the hepatic artery, change in TBA reactants level was slight. However, the mean value of TBA(More)
  • 1